We can’t show the full text here under this license. Use the link below to read it at the source.
Safety and efficacy of once‐weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial
Safety and effectiveness of weekly semaglutide compared to extra oral diabetes medicines in Japanese people with poorly controlled type 2 diabetes
AI simplified
Abstract
88.0% of participants receiving semaglutide reported adverse events, compared to 71.7% with an additional oral antidiabetic drug.
- Semaglutide 0.5 mg and 1.0 mg significantly reduced mean glycated hemoglobin (HbA1c) by 1.7% and 2.0%, respectively, compared to a 0.7% reduction with the additional oral antidiabetic drug.
- Body weight decreased by 1.4 kg and 3.2 kg in the semaglutide groups, while participants receiving the additional oral antidiabetic drug experienced a 0.4-kg weight increase.
- More than 80% of semaglutide-treated participants achieved an HbA1c concentration below 7.0%, meeting the target set by the Japanese Diabetes Society.
- Gastrointestinal adverse events were the most frequent in semaglutide groups but typically mild or moderate and diminished over time.
- No new safety issues were identified with semaglutide treatment.
AI simplified
Key numbers
1.7%
Reduction in HbA1c
Change in HbA1c with semaglutide 0.5 mg vs additional OAD
3.2 kg
Body weight change
Mean weight change with semaglutide 1.0 mg vs additional OAD
88.0%
Adverse events incidence
Proportion of participants reporting TEAEs with semaglutide 1.0 mg